CHICAGO, April 25, 2025 /PRNewswire/ -- Belay Diagnostics, a CLIA/CAP accredited laboratory focused on the development and commercialization of molecular diagnostics targeting central nervous system ...
GENT, Belgium & MALVERN, Pa. & TOKYO, January 28, 2026--(BUSINESS WIRE)--H.U. Group Holdings Inc. and its wholly-owned subsidiary Fujirebio today announced the availability of the Lumipulse G pTau 217 ...
Validation Data on More Than 100 Patients published in Journal of Molecular Diagnostics CHICAGO, April 25, 2025 /PRNewswire/ -- Belay Diagnostics, a CLIA/CAP accredited laboratory focused on the ...
Fujirebio's Lumipulse® G pTau217/β-Amyloid 1-42 Plasma Ratio test has the potential to shorten the Alzheimer's disease diagnostic journey and enable earlier intervention through its accessibility and ...
Longitudinal tumor-wide sampling of glioblastoma reveals diverse genomic drivers of the earliest clonal expansion at diagnosis and recurrence. Efficacy and biomarker analysis of phase 2 (P2) and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results